Resmed (RME) Stock Statistics & Valuation Metrics

Resmed has a market cap or net worth of EUR 29.48B. The enterprise value is EUR 31.29B.

Market Cap

EUR 29.48B

Enterprise Value

EUR 31.29B

Resmed has 140,657,070 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

140,657,070

Owned by Insiders

0.55%

Owned by Institutions

51.31%

Resmed’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 19.27%.

Return on Equity (ROE)

0.23

Return on Assets (ROA)

0.17

Return on Invested Capital (ROIC)

19.27%

Return on Capital Employed (ROCE)

0.25

Revenue Per Employee

497.22K

Profits Per Employee

133.97K

Employee Count

11,370

Asset Turnover

0.63

Inventory Turnover

2.33

The current PE Ratio of Resmed is 21.30. Resmed’s PEG ratio is 1.77.

PE Ratio

21.30

PS Ratio

5.74

PB Ratio

5.63

Price to FCF

11.56

Price to Operating Cash Flow

10.72

PEG Ratio

1.77

In the last 12 months, Resmed had revenue of 5.65B and earned 1.52B in profits. Earnings per share was 10.44.

Revenue

5.65B

Gross Profit

3.45B

Operating Income

1.91B

Pretax Income

1.92B

Net Income

1.52B

EBITDA

2.15B

Earnings Per Share (EPS)

10.44

In the last 12 months, operating cash flow was 3.12B and capital expenditures -273.23M, giving a free cash flow of 2.85B billion.

Operating Cash Flow

3.12B

Free Cash Flow

2.85B

Free Cash Flow per Share

19.92

Resmed pays an annual dividend of ―, resulting in a dividend yield of 1.08%

Dividend Per Share

―

Dividend Yield

1.08%

Payout Ratio

N/A

Free Cash Flow Yield

8.49%

Earnings Yield

4.67%

Beta

0.52

52-Week Price Change

-2.95%

50-Day Moving Average

202.92

200-Day Moving Average

191.48

Relative Strength Index (RSI)

47.50

Average Volume (3m)

30

Resmed upcoming earnings date is Jan 28, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Jan 28, 2027

Ex-Dividend Date

―

Resmed as a current ratio of 3.10, with Debt / Equity ratio of 12.54%

Current Ratio

3.10

Quick Ratio

2.42

Debt to Market Cap

0.02

Net Debt to EBITDA

-0.30

Interest Coverage Ratio

0.00

In the past 12 months, Resmed has paid 396.12M in taxes.

Income Tax

396.12M

Effective Tax Rate

0.21

Resmed EV to EBITDA ratio is 14.80, with an EV/FCF ratio of 11.64.

EV to Sales

5.78

EV to EBITDA

14.80

EV to Free Cash Flow

11.64

EV to Operating Cash Flow

10.62

Resmed has EUR 1.01B in cash and marketable securities with EUR 610.58M in debt, giving a net cash position of EUR 400.16M billion.

Cash & Marketable Securities

EUR 1.01B

Total Debt

EUR 610.58M

Net Cash

EUR 400.16M

Net Cash Per Share

EUR 2.84

Tangible Book Value Per Share

EUR 18.16

Gross margin is 61.18%, with operating margin of 33.13%, and net profit margin of 27.79%.

Gross Margin

61.18%

Operating Margin

33.13%

Pretax Margin

35.09%

Net Profit Margin

27.79%

EBITDA Margin

39.07%

EBIT Margin

35.09%

The average price target for Resmed is EUR 234.70, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

EUR 234.70

Price Target Upside

13.05% Upside

Analyst Consensus

Moderate Buy

Analyst Count

12

Revenue Growth Forecast

3.63%

EPS Growth Forecast

6.61%

Smart Score

8

AI Score

―